MBA/BSN/RN. I specialize in biotech investment analysis, integrating clinical expertise with a solid foundation in business strategy. My approach leverages detailed risk-return charts and DCF analyses to clearly communicate the investment potential and associated risks. I advocate for a barbell portfolio strategy, with 90% allocated to secure assets such as Treasuries and broad-market ETFs, and 10% to high-alpha stocks. This balanced approach ensures that all recommendations are made within a context of strategic risk management.Given the market's inherent efficiency and the significant role of randomness in returns, my analysis is deeply influenced by 'Superforecasting' and 'Antifragile' principles, focusing on probabilistic forecasting and robust strategies that minimize risk while maximizing potential gains.For inquiries, collaborations, or opportunities, please contact me at stephenayers42@gmail.com.